Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload

Cardiovascular Research

Volumn 86, Issue 3, 2010, Pages 461-470

  Doenst, Torsten ^a   Pytel, Gracjan ^a   Schrepper, Andrea ^a   Amorim, Paulo ^a   Färber, Gloria ^a   Shingu, Yasushige ^a   Mohr, Friedrich W ^a   Schwarzer, Michael ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Echocardiography; Heart failure; Pressure overload; Substrate oxidation predictive for diagnosis of heart failure

Indexed keywords

FATTY ACID; GLUCOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ARCH; ARTICLE; BODY WEIGHT; CONTRACTILE DYSFUNCTION; CONTROLLED STUDY; DISEASE COURSE; ECHOCARDIOGRAPHY; ENERGY METABOLISM; EX VIVO STUDY; FATTY ACID OXIDATION; GLUCOSE OXIDATION; HEART CONTRACTION; HEART DILATATION; HEART DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HEART HYPERTROPHY; HEART MITOCHONDRION; HEART VENTRICLE OVERLOAD; IN VIVO STUDY; INSPIRATORY CAPACITY; ISOLATED HEART; LIGATION; LUNG CONGESTION; LUNG WEIGHT; MALE; NONHUMAN; PREDICTION; PRESSURE MEASUREMENT; PRIORITY JOURNAL; PROGNOSIS; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD PRESSURE; CELL RESPIRATION; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; FATTY ACIDS; GLUCOSE; HEART FAILURE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MITOCHONDRIA, HEART; MYOCARDIAL CONTRACTION; MYOCARDIUM; OXIDATION-REDUCTION; PULMONARY EDEMA; RATS; RATS, SPRAGUE-DAWLEY; STROKE VOLUME; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 77952364346     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp414     Document Type: Article

References (46)

1. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001;141:334-341.
2. Kupari M, Turto H, Lommi J. Left ventricular hypertrophy in aortic valve stenosis: preventive or promotive of systolic dysfunction and heart failure? Eur Heart J 2005;26: 1790-1796.
3. Feldman DS, Carnes CA, Abraham WT, Bristow MR. Mechanisms of disease: beta-adrenergic receptors-alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med 2005;2:475-483.
4. Huss JM, Kelly DP. Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest 2005;115:547-555.
5. Gwathmey JK, Copelas L, MacKinnon R, Schoen FJ, Feldman MD, Grossman W et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 1987;61:70-76.
6. Chandler MP, Kerner J, Huang H, Vazquez E, Reszko A, Martini WZ et al. Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation. Am J Physiol Heart Circ Physiol 2004;287:H1538-H1543.
7. Osorio JC, Stanley WC, Linke A, Castellari M, Diep QN, Panchal AR et al. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 2002;106:606-612.
8. Neubauer S. The failing heart\an engine out of fuel. N Engl J Med 2007;356: 1140-1151.
9. Taegtmeyer H. Switching metabolic genes to build a better heart. Circulation 2002; 106:2043-2045.
10. Zaha V, Grohmann J, Gobel H, Geibel A, Beyersdorf F, Doenst T. Experimental model for heart failure in rats\induction and diagnosis. Thorac Cardiovasc Surg 2003;51: 211-215.
11. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol 1976;37:7-11.
12. Perlini S. Determinants of left ventricular mass in hypertensive heart disease: a complex interplay between volume, pressure, systolic function and genes. J Hypertens 2007;25:1341-1342.
13. Salemi VM, Pires MD, Cestari IN, Cestari IA, Picard MH, Leirner AA et al. Echocardio-graphic assessment of global ventricular function using the myocardial performance index in rats with hypertrophy. Artif Organs 2004;28:332-337.
14. Sjaastad I, Sejersted OM, Ilebekk A, Bjornerheim R. Echocardiographic criteria for detection of postinfarction congestive heart failure in rats. J Appl Physiol 2000;89: 1445-1454.
15. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocar-diogr 2005;18:1440-1463.
16. Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005; 28:1936-1940.
17. Schwarzer M, Faerber G, Rueckauer T, Blum D, Pytel G, Mohr FW et al. The metabolic modulators, Etomoxir and NVP-LAB121, fail to reverse pressure overload induced heart failure in vivo. Basic Res Cardiol 2009;104:547-557.
18. Taegtmeyer H, Hems R, Krebs HA. Utilization of energy-providing substrates in the isolated working rat heart. Biochem J 1980;186:701-711.
19. Fischer-Rasokat U, Beyersdorf F, Doenst T. Insulin improves recovery of contractile function equal to ischemic preconditioning in rat heart. Basic Res Cardiol 2003;98: 329-336.
20. Doenst T, Guthrie PH, Chemnitius JM, Zech R, Taegtmeyer H. Fasting, lactate, and insulin improve ischemia tolerance in rat heart: a comparison with ischemic preconditioning. Am J Physiol 1996;270:H1607-H1615.
21. Doenst T, Taegtmeyer H. Complexities underlying the quantitative determination of myocardial glucose uptake with 2-deoxyglucose. J Mol Cell Cardiol 1998;30: 1595-1604.
22. King LM, Opie LH. Glucose and glycogen utilisation in myocardial ischemia-changes in metabolism and consequences for the myocyte. Mol Cell Biochem 1998;180:3-26.
23. Palmer JW, Tandler B, Hoppel CL. Biochemical properties of subsarcolemmal and interfibrillar mitochondria isolated from rat cardiac muscle. J Biol Chem 1977;252: 8731-8739.
24. Moghaddas S, Stoll MS, Minkler PE, Salomon RG, Hoppel CL, Lesnefsky EJ. Preservation of cardiolipin content during aging in rat heart interfibrillar mitochondria. J Gerontol A Biol Sci Med Sci 2002;57:B22-B28. (Pubitemid 34074437)
25. Tomec RJ, Hoppel CL. Carnitine palmitoyltransferase in bovine fetal heart mitochondria. Arch Biochem Biophys 1975;170:716-723.
26. Chance B, Williams GR. Respiratory enzymes in oxidative phosphorylation. I. Kinetics of oxygen utilization. J Biol Chem 1955;217:383-393.
27. Estabrook RW. Mitochondrial respiratory control and the polarographic measurement of ADP:O ratios. In: Estabrook RW, Pullman ME eds. Methods in Enzymology. New York: Academic Press; 1967. p41-47.
28. Zar JH. Biostatistical Analysis. Upper Saddle River: Prentice-Hall, Inc; 1999.
29. Schmidt HD, Scheer RD. Quantitative data on the afterload dependence of left ventricular dp/dtmax in isolated canine hearts. Basic Res Cardiol 1981;76:89-105.
30. Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 1996;94: 2837-2842.
31. Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation 2007;116:434-448.
32. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093-1129.
33. O'Donnell JM, Fields AD, Sorokina N, Lewandowski ED. The absence of endogenous lipid oxidation in early stage heart failure exposes limits in lipid storage and turnover. J Mol Cell Cardiol 2008;44:315-322.
34. Abel ED, Kaulbach HC, Tian R, Hopkins JC, Duffy J, Doetschman T et al. Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J Clin Invest 1999;104:1703-1714.
35. Hansson A, Hance N, Dufour E, Rantanen A, Hultenby K, Clayton DA et al. A switch in metabolism precedes increased mitochondrial biogenesis in respiratory chain-deficient mouse hearts. Proc Natl Acad Sci USA 2004;101:3136-3141.
36. King KL, Stanley WC, Rosca M, Kerner J, Hoppel CL, Febbraio M. Fatty acid oxidation in cardiac and skeletal muscle mitochondria is unaffected by deletion of CD36. Arch Biochem Biophys 2007;467:234-238.
37. Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hypergly-cemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005;146:5341-5349.
38. Belke DD, Betuing S, Tuttle MJ, Graveleau C, Young ME, Pham M et al. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest 2002;109:629-639.
39. Lehman JJ, Boudina S, Banke NH, Sambandam N, Han X, Young DM et al. The tran-scriptional coactivator PGC-1alpha is essential for maximal and efficient cardiac mito-chondrial fatty acid oxidation and lipid homeostasis. Am J Physiol Heart Circ Physiol 2008;295:H185-H196.
40. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-2442.
41. Borlaug BA, Melenovsky V, Russell SD, Kessler K, Pacak K, Becker LC et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 2006;114:2138-2147.
42. Morgan EE, Faulx MD, McElfresh TA, Kung TA, Zawaneh MS, Stanley WC et al. Validation of echocardiographic methods for assessing left ventricular dysfunction in rats with myocardial infarction. Am J Physiol Heart Circ Physiol 2004;287: H2049-H2053.
43. Bergmann SR. Imaging of myocardial fatty acid metabolism with PET. J Nucl Cardiol 2007;14:S118-S124.
44. Davila-Roman VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyo-pathy. J Am Coll Cardiol 2002;40:271-277.
45. Tuunanen H, Engblom E, Naum A, Scheinin M, Nagren K, Airaksinen J et al. Decreased myocardial free fatty acid uptake in patients with idiopathic dilated cardiomyopathy: evidence of relationship with insulin resistance and left ventricular dysfunction. J Card Fail 2006;12:644-652.
46. Mazumder PK, O'Neill BT, Roberts MW, Buchanan J, Yun UJ, Cooksey RC et al. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 2004;53:2366-2374.